Search form

 

Press Releases


Please select a year to review:
           

2014 | 2013 | 2012 | 2011 | 2010 | 2008 | 2007 | 2006 | 2005 | 2004

2012

December 10, 2012
Aptalis Pharma U.S., Inc. Announces U.S. Commercial Availability of ULTRESA™ (Pancrelipase) Delayed-Release Capsules

August 14, 2012
Aptalis Pharma Announces U.S. Commercial Availability of VIOKACE™ (Pancrelipase) Tablets

April 18, 2012
Aptalis Pharma Inc. Announces Receipt of Requisite Consents to Amend Indenture Governing Its 12 3/4% Senior Notes, Entry Into Supplemental Indenture, ...

April 18, 2012
Aptalis Pharma Inc. Announces Receipt of Requisite Consents to Amend Indenture Governing Its 12 3/4% Senior Notes, Entry Into Supplemental Indenture, Amendment of Its Senior Secured Credit Facilities, Settlement of 12 3/4% Senior Notes Tendered and Redemption of All Outstanding 12 3/4% Senior Notes

April 05, 2012
Aptalis Pharma Inc. Commences Tender Offer for Its 12 3/4% Senior Notes Due 2016 and Solicitation of Consents

March 29, 2012
Aptalis Pharma Announces Intention to Enter Into Senior Secured Term Loan Credit Facility

March 16, 2012
Aptalis Pharma Begins Promotion of RECTIV™ to Physicians in the U.S.

March 01, 2012
Aptalis Pharma Announces FDA Approval of ULTRESA™ Pancrelipase Delayed Release Capsules and VIOKACE™ Pancrelipase Tablets

January 18, 2012
Aptalis Pharma Announces FDA Approval of NDA for Oral Powder Formulation of Viread®, Co-Developed With Gilead Sciences, Inc.

January 09, 2012
Aptalis Pharma Announces Agreement to Market RECTIV™ in the U.S.